Junji Bio key facts
- Developer of biosynthesis designed to provide overall solutions for molecular diagnosis, nucleic acid chemistry, synthetic biology and antibody drug development.
- It has raised $14.1M; the latest was Later Stage VC ($14.1M) in Dec 2025.
- Notable investors include Hangzhou Dongfang Jiafu Asset Management, Optics Valley Industry Investment, Lianyungang Jinhai Venture Capital, Jiangsu Jinqiao Private Equity Fund Management, Tenyall Investment.
- Status: Privately Held (backing).
- ·Watch Junji Bio: the Monday email on marks, rounds and moves
Junji Bio funding rounds
No funding rounds for Junji Bio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Junji Bio investors
5 investors are on record for Junji Bio, including Hangzhou Dongfang Jiafu Asset Management, Optics Valley Industry Investment, Lianyungang Jinhai Venture Capital and Jiangsu Jinqiao Private Equity Fund Management.
About Junji Bio
Developer of biosynthesis designed to provide overall solutions for molecular diagnosis, nucleic acid chemistry, synthetic biology and antibody drug development. The company focuses on the research and development of life science robot technology and the application of artificial intelligence in life science, thereby providing customers with high-quality customized chemical synthesis, biosynthesis and molecular biology-related services.
- Sector
- Healthcare
- HQ
- Suzhou, China
- Founded
- 2020
- Website
- gentlegen.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.
Junji Bio doesn't have a valuation on record yet — one is published once a priced round, a reported valuation, fund marks, or secondary prints surface in our sources. The rest of the record below builds toward it.